What is SpectraWAVE?
Founded in 2017, SpectraWAVE specializes in the development of high-precision diagnostic tools for the cardiac catheterization laboratory. The company's flagship HyperVue Imaging System represents a significant technological leap, combining DeepOCT imaging with near-infrared spectroscopy (NIRS). This dual-modality approach provides interventionalists with granular, real-time data, facilitating more accurate treatment decisions for patients suffering from arterial plaque buildup. As a privately held entity, SpectraWAVE operates at the intersection of medical imaging and computational analytics, targeting a market segment where precision is directly correlated with improved long-term patient outcomes.
How much funding has SpectraWAVE raised?
SpectraWAVE has raised a total of $63.2M across 2 funding rounds:
Series A
$13.2M
Series B
$50M
Series A (2021): $13.2M with participation from Deerfield Communications Inc
Series B (2024): $50M led by Lumira Ventures, Johnson & Johnson Innovation, and Heartwork
Key Investors in SpectraWAVE
Lumira Ventures
Canada's largest life sciences venture capital firm, Lumira Ventures focuses on scaling healthcare innovators from early-stage development to commercialization.
Johnson & Johnson Innovation
A global leader in healthcare innovation, this division partners with early-stage businesses to accelerate the development of transformational medical devices and pharmaceuticals.
Heartwork
A design-focused manufacturing firm that provides specialized workspace solutions, supporting operational efficiency across diverse sectors including healthcare.
What's next for SpectraWAVE?
With the infusion of this latest capital, SpectraWAVE is expected to accelerate the commercial deployment of the HyperVue Imaging System and expand its clinical footprint. The company is likely to focus on scaling its manufacturing capabilities and deepening its integration within major cardiac centers. Furthermore, the strategic backing from industry-leading investors suggests a roadmap focused on continuous product iteration and the potential for future enhancements to the HyperVue platform, ensuring that the company remains at the forefront of diagnostic innovation in the treatment of coronary artery disease.
See full SpectraWAVE company page
